Purchase this article with an account.
E. Donnenfeld, C. Roberts, H. Perry, R. Solomon, J. Wittpenn, M. McDonald; Efficacy of Topical Cyclosporine versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1066. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effect of topical cyclosporine A 0.05% (Restasis; Allergan, Inc.; Irvine, CA), on quality of vision in patients undergoing cataract surgery with a multifocal intraocular lens (IOL).
A multicenter, randomized, masked, prospective clinical trial to evaluate the effect of cyclosporine A 0.05% versus an artificial tear on the quality of vision in 40 eyes of 20 patients bilaterally implanted with the ReZoom® IOL (AMO, Santa Ana, CA). Masked study medications were instilled 2 times a day for 1 month preoperatively and 2 months postoperatively in one eye and the second eye randomly received the artificial tear. UCVA, BCVA, mesopic and photopic contrast sensitivity under high-contrast and low-contrast illumination, and topography were measured unilaterally at 2 months following implantation in each eye.
At 2 months following the second eye implantation, the eyes that received the cyclosporine A had significantly improved mesopic and photopic contrast sensitivity compared to eyes not receiving cyclosporine A and there was a trend towards improved UCVA and BCVA in the cyclosporine A treated eyes.
The preoperative and postoperative use of cyclosporine A 0.05% significantly improved visual outcomes in patients implanted with the ReZoom® multifocal IOL.
www.clinicaltrials.gov NCT00349583. Registered with WIRB
This PDF is available to Subscribers Only